Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer

JAMA

Volumn 305, Issue 22, 2011, Pages 2320-2326

  Kesselheim, Aaron S ^a   Myers, Jessica A ^a   Avorn, Jerry ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; BENDAMUSTINE; BEVACIZUMAB; CABAZITAXEL; CETUXIMAB; CLOFARABINE; DASATINIB; DEGARELIX; ERIBULIN; ERLOTINIB; EVEROLIMUS; IXABEPILONE; LAPATINIB; LENALIDOMIDE; NELARABINE; NILOTINIB; OFATUMUMAB; ORPHAN DRUG; PANITUMUMAB; PAZOPANIB; PEMETREXED; PRALATREXATE; ROMIDEPSIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; UNINDEXED DRUG; VORINOSTAT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); COLON CARCINOMA; COLORECTAL CARCINOMA; CUTANEOUS T CELL LYMPHOMA; DRUG APPROVAL; DRUG LEGISLATION; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; GASTROINTESTINAL STROMAL TUMOR; GOVERNMENT REGULATION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOBLASTOMA; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CARCINOMA; T CELL LYMPHOMA; TREATMENT OUTCOME; UNITED STATES;

EID: 79958036418     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.769     Document Type: Article

References (31)

1. Designation of Drugs for Rare Diseases or Conditions, 21 USC §360bb(a)(2) (2008).
2. Office of the Inspector General. Orphan Drug Act: implementation and impact. May 2011. http://oig.hhs.gov/oei/reports/oei-09-00-00380.pdf. Accessed April 21, 2011.
3. Wellman-Labadie O, Zhou Y. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy. 2010;95(2-3):216-228.
4. Haffner ME. Adopting orphan drugs - two dozen years of treating rare diseases. N Engl J Med. 2006; 354(5):445-447. (Pubitemid 43200295)
5. Coté T, Kelkar A, Xu K, Braun MM, Phillips MI. Orphan products: an emerging trend in drug approvals. Nat Rev Drug Discov. 2010;9(1):84.
6. Yin W. R&D policy, agency costs and innovation in personalized medicine. J Health Econ. 2009; 28(5):950-962.
7. US Food and Drug Administration. Mylotarg (gemtuzumab ozogamicin): market withdrawal. June 21, 2010. http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm216458.htm. Accessed April 21, 2011.
8. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001;7(6):1490-1496. (Pubitemid 32708610)
9. Hirschler B. UK says Novartis, Bristol cancer drugs too costly. February 8, 2010. http://www.reuters.com/article/2010/02/09/britain-cancer- idUSLDE61718V20100209. Accessed April 21, 2011.
10. Applications for FDA Approval to Market a New Drug, 21 CFR §314.126 (2009).
11. US Food and Drug Administration. Developing products for rare diseases and conditions. January 18, 2011. http://www.fda.gov/ForIndustry/ DevelopingProductsforRareDiseasesConditions/default.htm. Accessed April 21, 2011.
12. Buckley BM. Clinical trials of orphan medicines. Lancet. 2008;371(9629):2051-2055. (Pubitemid 351799863)
13. Kesselheim AS. Innovation and the Orphan Drug Act, 1983-2009: the regulatory and clinical characteristics of approved orphan drugs. In: Field MJ, Boat TF, eds. Accelerating Rare Diseases Research and Orphan Product Development. Washington, DC: National Academy Press; 2010.
14. Mitsumoto J, Dorsey ER, Beck CA, Kieburtz K, Griggs RC. Pivotal studies of orphan drugs approved for neurological diseases. Ann Neurol. 2009;66 (2):184-190.
15. US Food and Drug Administration. Search orphan drug designation and approvals. http://www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm. Accessed April 21, 2011.
16. National Cancer Institute. A to Z list of cancers. http://www.cancer.gov/ cancertopics/types/alphalist. Accessed February 18, 2011.
17. US Food and Drug Administration. NME drug and new biologic approvals. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/ucm121136.htm. Accessed April 21, 2011.
18. US Food and Drug Administration. Postmarket requirements and commitments. January 31, 2011. http://www.accessdata.fda.gov/scripts/cder/pmc/index.cfm. Accessed April 21, 2011.
19. Simes RJ. An improved Bonferroni procedure for multiple tests of significance. Biometrika. 1986; 73:751-754.
20. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2011. http://www.R-project.org/. Accessed May 11, 2011.
21. Avorn J. Paying for drug approvals - who's using whom? N Engl J Med. 2007;356(17):1697-1700.
22. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol. 2003; 21(7):1404-1411. (Pubitemid 46606423)
23. Tsimberidou AM, Braiteh F, Stewart DJ, Kurzrock R. Ultimate fate of oncology drugs approved by the US Food and Drug Administration without a randomized trial. J Clin Oncol. 2009;27(36):6243-6250.
24. Dagher R, Johnson J, Williams G, Keegan P, Pazdur R. Accelerated approval of oncology products: a decade of experience. J Natl Cancer Inst. 2004;96 (20):1500-1509. (Pubitemid 39445531)
25. Psaty BM, Prentice RL. Minimizing bias in randomized trials: the importance of blinding. JAMA. 2010;304(7):793-794.
26. Miller FG, Joffe S. Equipoise and the dilemma of randomized clinical trials. N Engl J Med. 2011; 364(5):476-480.
27. McKee AE, Farrell AT, Pazdur R, Woodcock J. The role of the US Food and Drug Administration review process: clinical trial endpoints in oncology. Oncologist. 2010;15(suppl 1):13-18.
28. Robert NJ, Die? ras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011; 29(10):1252-1260.
29. Avorn J. Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York, NY: Alfred A Knopf; 2005.
30. Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R. Accelerated approval of oncology products: the Food and Drug Administration experience. J Natl Cancer Inst. 2011;103(8):636-644.
31. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010; 7(5):245-257.